The Global Health Body Sounds Alert Over Acute Shortage of Weight-Loss Injections
Fewer than 10% of individuals that would benefit from obesity jabs such as Wegovy can access them, warns the WHO as it publishes its inaugural recommendations on the medications.
Considering over a billion people worldwide currently living with obesity, it is advocating for increased and just availability to GLP-1 medication.
According to forecasts, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"Our latest guidelines acknowledges that obesity is a chronic disease that can be addressed with comprehensive and lifelong treatment," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are major obstacles to universal access to the injections that can aid individuals in losing substantial body mass, explains the body.
GLP-1 Therapy Shortage
Despite the present most optimistic case, the production of these medications could only cover approximately 100 million people – fewer than 10% of those who need them, per the health organization.
The guideline encourages governments and firms to expand availability, through approaches such as patent sharing.
Exclusive production rights on semaglutide – the primary ingredient of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.
How Obesity Jabs Work
GLP-1 drugs replicate a body's own hormone to delay gastric emptying, suppress the appetite and increase feelings of fullness so people reduce food intake.
People commonly begin shedding pounds within a few weeks of beginning the weekly injections.
Research indicates patients may regain a significant portion after a year of discontinuing the medication, as their typical appetite resume.
To be above a healthy weight raises your chance for developing diseases, such as type 2 diabetes, heart disease, stroke, and some malignancies.
Excess weight impacts people in all nations and was linked to millions of fatalities worldwide in 2024, as per the health agency.